Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Current Deferred Revenue for 4 consecutive years, with $7.7 million as the latest value for Q4 2024.

  • Quarterly Current Deferred Revenue changed N/A to $7.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2024, changed N/A year-over-year, with the annual reading at $7.7 million for FY2024, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2024 was $7.7 million at Relay Therapeutics, up from $24000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $7.7 million in Q4 2024, with the low at $15000.0 in Q2 2023.
  • Average Current Deferred Revenue over 4 years is $1.1 million, with a median of $207000.0 recorded in 2021.
  • The sharpest move saw Current Deferred Revenue plummeted 79.95% in 2022, then crashed 81.93% in 2023.
  • Over 4 years, Current Deferred Revenue stood at $248000.0 in 2021, then tumbled by 66.53% to $83000.0 in 2022, then tumbled by 71.08% to $24000.0 in 2023, then surged by 31895.83% to $7.7 million in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $7.7 million, $24000.0, and $15000.0 for Q4 2024, Q3 2023, and Q2 2023 respectively.